DTIL

Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company\'s pipeline consists of multiple \'off-the-shelf\' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

Precision BioSciences, Inc. (DTIL) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Profitability (C). The rating has held at C+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
B
Factor Score 3.2 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 38.0
EV / EBITDA -6.0
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M 28.0%
Price Return 12M 54.7%
Catalyst Signal 0.00
Market Cap $362.6M
TTM Revenue $45.0M
Price / Sales 8.1
ROE -115.3%

Historical Factor Score Progression

Held C+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.8) B (3.2) C (2.4) B- (3.0) C+ (2.6) C+ (2.8)
2026-11-04 B- (3.0) C (2.3) C (2.5) C (2.5) C+ (2.7) C+ (2.6)
2026-10-28 B- (3.0) C (2.2) C (2.5) C (2.5) C+ (2.7) C+ (2.6)
2026-10-21 B- (3.0) C (2.2) C (2.5) C (2.3) C+ (2.6) C+ (2.5)
2026-10-14 B- (3.0) C (2.2) C (2.5) C- (2.1) C+ (2.6) C (2.5)
Page 1 of 8
…